4d Molecular Therapeutics, Inc.
A maker of genetic medicines, 4D Molecular Therapeutics engineers custom viral delivery vehicles to treat diseases of the eye, lung, and heart. Founded in 2013 by a UC Berkeley professor and a biotech entrepreneur who met at a university innovation hub, the company got its start in a garage incubator. Its name reflects the four dimensions of optimization its scientists pursue when designing the adeno-associated virus vectors that carry therapeutic genes into the body.
Granted 50.0K · Sold 185.7K
Granted 2.2K · Sold 779
Granted 9.3K
Granted 15.8K · Sold 22.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kirn DavidSee Remarks, Director · 5 transactions | -22% | 825.8K | 50.0K | — | 185.7K |
| Gupta AshooVP, Finance and Controller · 8 transactions | — | 47.1K | 2.2K | — | 779 |
| Theuer CharlesDirector · 1 transaction | +28.8% | 41.7K | 9.3K | — | — |
| Bizily ScottChief Legal Officer · 12 transactions | +153.1% | 18.4K | 15.8K | — | 22.2K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -208.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.